BridgeBio trust plans $2.49M BBIO share sale

BridgeBio Pharma, Inc. (BBIO) received a notice that the Kumar Haldea Family Irrevocable Trust plans to sell 30,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services.

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) received a notice that the Kumar Haldea Family Irrevocable Trust plans to sell 30,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares relate to a 03/26/2016 acquisition described as “Conversion Management Incentive Units.” A figure of $2,489,400.00 is listed for these 30,000 shares, and 195,487,474 common shares are shown as outstanding as of 08/19/2026 on NASDAQ. Over the prior three months, related 10b5‑1 sales are reported for Neil Kumar and related trusts, including multiple transactions of 20,000–34,980 shares of BBIO common stock with aggregate proceeds in the low‑ to mid‑million‑dollar range.

Key Figures

Shares to be sold: 30,000 shares Aggregate value of shares to be sold: $2,489,400.00 Shares outstanding: 195,487,474 shares +5 more

8 metrics

Shares to be sold 30,000 shares Common stock covered by the notice for the Kumar Haldea Family Irrevocable Trust

Aggregate value of shares to be sold $2,489,400.00 Amount listed for 30,000 common shares in the securities information section

Shares outstanding 195,487,474 shares BridgeBio common shares shown as outstanding as of 08/19/2026

Neil Kumar 10b5-1 sale 05/21/2026 26,103 shares; $1,812,521.84 Common stock sold under a 10b5-1 plan for Neil Kumar

Neil Kumar 10b5-1 sale 08/18/2026 34,980 shares; $2,886,993.85 Common stock sold under a 10b5-1 plan for Neil Kumar

Haldea Revocable Trust 10b5-1 sale 06/05/2026 20,000 shares; $1,357,538.00 Common stock sold under a 10b5-1 plan for Kumar Haldea Revocable Trust

Haldea Family Irrevocable Trust 10b5-1 sale 06/05/2026 20,000 shares; $1,357,538.00 Common stock sold under a 10b5-1 plan for Kumar Haldea Family Irrevocable Trust

Haldea Family Irrevocable Trust 10b5-1 sale 06/04/2026 20,000 shares; $1,349,106.00 Common stock sold under a 10b5-1 plan for Kumar Haldea Family Irrevocable Trust

Key Terms

Rule 144, 10b5-1, Management Incentive Units, Irrevocable Trust, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 regulatory

"10b5-1 Sales for NEIL KUMAR 3160 PORTER DRIVE SUITE 250"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Management Incentive Units financial

"Conversion Management Incentive Units | Issuer | | | 30000"

Irrevocable Trust financial

"KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019"

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

Revocable Trust financial

"10b5-1 Sales for KUMAR HALDEA REVOCABLE TRUST 3160 PORTER"

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does this Form 144 filing mean for BridgeBio Pharma, Inc. (BBIO)?

It reports an intended sale of 30,000 BBIO common shares by the Kumar Haldea Family Irrevocable Trust under Rule 144. The notice lists broker details, acquisition background, and recent related 10b5‑1 sales by associated parties.

How many BridgeBio (BBIO) shares are planned to be sold and by whom?

The notice covers 30,000 shares of BridgeBio common stock for the account of the Kumar Haldea Family Irrevocable Trust. Morgan Stanley Smith Barney LLC Executive Financial Services is listed as the broker handling the transaction.

What dollar amount is associated with the 30,000 BBIO shares in this Form 144?

The filing lists an amount of $2,489,400.00 for the 30,000 common shares to be sold. This represents the aggregate value figure disclosed alongside the share amount in the securities information section.

How many BridgeBio (BBIO) shares are shown as outstanding in this notice?

The document shows 195,487,474 BridgeBio common shares as outstanding as of 08/19/2026. This number serves as context for the company’s total common stock compared with the 30,000 shares covered by the notice.

What is the background of the BBIO shares being sold by the trust?

The 30,000 BBIO shares are linked to a 03/26/2016 transaction described as “Conversion Management Incentive Units”. The issuer is listed as the source in that acquisition, indicating the shares originated from a management incentive conversion.

What recent 10b5-1 sales related to BBIO are disclosed in this filing?

The notice lists several 10b5‑1 sales over three months, including Neil Kumar’s sales of 26,103 shares for $1,812,521.84 and 34,980 shares for $2,886,993.85, plus multiple 20,000‑share sales by related Haldea trusts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 04:34 PM Accepted by SEC EDGAR 08/19/2026 - 04:34 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001742485
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BridgeBio Pharma, Inc.
SEC File Number	001-38959
Address of Issuer	3160 PORTER DRIVE SUITE 250 Palo Alto CALIFORNIA 94304
Phone	6503919740
Name of Person for Whose Account the Securities are To Be Sold	KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	30000	2489400.00	195487474	08/19/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/26/2016	Conversion Management Incentive Units	Issuer			30000	03/26/2016	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for NEIL KUMAR 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	08/18/2026	34980	2886993.85
10b5-1 Sales for KUMAR HALDEA REVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	06/05/2026	20000	1357538.00
10b5-1 Sales for KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	06/05/2026	20000	1357538.00
10b5-1 Sales for KUMAR HALDEA REVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	06/04/2026	20000	1349106.00
10b5-1 Sales for KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	06/04/2026	20000	1349106.00
10b5-1 Sales for NEIL KUMAR 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	05/21/2026	26103	1812521.84

144: Remarks and Signature

Remarks
Date of Notice	08/19/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Neil Kumar
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)